N-acetylcysteine has been recently tested in treating refractory TTP as it could substitute ADAMTS-13 and reduce the size of ultra-large vWF multimers; however, the use is still under clinical trials and needs further studies to support its effectiveness in treating refractory TTP. The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.